New Journey(SZ:002219)2022-12-06 09:54Group 1: Regulatory Issues - The company received a "Notice of Investigation" from the China Securities Regulatory Commission (CSRC) due to suspected violations of securities laws, leading to a formal investigation [2] - The company has fulfilled its disclosure obligations and has not yet received conclusive opinions from relevant authorities [2] Group 2: Management Changes - Several executives, including former Chairman Que Wenbin, have left the company, which some speculate is related to the strategic shift from pharmaceuticals to healthcare services [2] - The departure of these executives represents a small percentage of the overall management team, and the company believes it will not adversely affect daily operations [2] Group 3: Financial Performance - In the first half of the year, sales expenses increased by 334.40%, primarily due to increased costs associated with drug and toothpaste sales [3] - The increase in sales expenses is attributed to a low base from the previous year and adjustments in sales policies due to new pharmaceutical regulations [3] Group 4: Hospital Performance - The company has experienced rapid growth in its medical services sector, but some previously acquired hospitals are facing stagnation in organic growth [2] - To address this, the company plans to enhance hospital services through hardware upgrades and software improvements, including the introduction of advanced medical technologies and the establishment of a shared platform for its hospitals [2]